This Project Grant award of $535,153 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund a large-scale, single-cell characterization of molecular and cellular networks involved in mood regulation in major depressive disorder (MDD). The project aims to identify transcriptomic changes associated with MDD in a sample of 800 subjects across three key brain regions: the anterior cingulate cortex, basolateral amygdala, and...
The National Institute of Mental Health (NIMH) awarded a $2,220,017 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Lieber Institute for Brain Development in Baltimore, Maryland. The grant's objective is to generate single-cell transcriptomic profiles to study molecular changes associated with major depressive disorder (MDD) in the mood regulation circuitry of the brain, including the anterior cingulate cortex, basolateral amygdala, and hippocampus. The research aims to...
This federal Project Grant award of $729,821, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports research to investigate the role of long non-coding RNAs (lncRNAs) in the epigenomic reprogramming and transcriptional repatterning associated with major depressive disorder (MDD). The University of Alabama at Birmingham will conduct this 1-year research project to examine how cell type-specific changes in nuclear...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $184,476.00 to the University of Southern California to conduct large-scale brain mapping research on bipolar disorder (BD) and major depressive disorder (MDD). The key objectives are to: 1) Apply a standardized voxel-wise brain mapping method across a target sample of 12,000 subjects (3,500 BD, 8,500 healthy controls) to analyze focal morphometric...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), seeks to advance the understanding of the etiology of major depression by integrating genetic, epidemiological, developmental, and molecular genetic data from national health registers in Denmark and Sweden. The $593,104 award to Virginia Commonwealth University will fund a 5-year research project to: 1) harmonize data on genetic and environmental risk...
This Project Grant award, totaling $576,926 and awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), aims to characterize the cellular and molecular changes in the human anterior hippocampus (a brain region critical for emotion regulation) across the menopausal transition. The research will utilize single-nucleus multiome analysis and micro-C analysis to define the shifts in gene expression, chromatin states, and 3D genome...
The National Institute of Mental Health (NIMH) awarded a $162,000 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the Research Foundation For Mental Hygiene, Inc. (RFMH), doing business as the New York Psychiatric Center. The project, titled "Transcriptional Diversity of Human Mediodorsal Thalamus and Its Role in Psychiatric Disease", will investigate the transcriptional signatures and genetic factors underlying differences in thalamocortical connectivity...
This $718,662 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research to characterize the genetic regulation of alternative polyadenylation (APA) in the developing human brain and its contribution to neuropsychiatric disorders like autism spectrum disorder (ASD) and schizophrenia (SCZ). The project aims to generate a comprehensive atlas of APA regulation across neurodevelopment, leveraging data from...
This $441,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research at Yale University to investigate the molecular changes in the brain that link cannabis use disorder and major depressive disorder. The researchers will use innovative single-cell genomics to identify transcriptomic and chromatin alterations in two key brain regions from 120 donors with cannabis use disorder, major...
This $21.4 million cooperative agreement from the National Institute of Mental Health will fund research to identify gene regulatory elements that can target and manipulate specific neuronal cell types and brain circuits across species, including in human organoids. Awarded on September 1, 2022 to the Broad Institute, Inc. with completion by August 31, 2025, the funding supports the Mental Health Research Grants program. The Broad Institute and collaborators at Harvard University will profile...
2/2 LARGE-SCALE, SINGLE-CELL CHARACTERIZATION OF MOLECULAR AND CELLULAR NETWORKS OF MOOD REGULATION CIRCUITRY IN MAJOR DEPRESSIVE DISORDER - WHILE THERE IS STRONG EVIDENCE SUPPORTING THE ROLE OF THE ANTERIOR CINGULATE CORTEX, BASOLATERAL AMYGDALA, AND THE HIPPOCAMPUS (ACC, BLA, HIPP) AS A KEY NEURAL NETWORK REGULATING MOOD, AND THEREFORE CENTRAL TO THE PATHOPHYSIOLOGY OF MAJOR DEPRESSIVE DISORDER (MDD), MUCH REMAINS UNKNOWN, INCLUDING WHICH GENE PATHWAYS AND WHICH SPECIFIC CELL TYPES PLAY A PRIMARY CAUSAL ROLE MEDIATING ALTERATIONS IN THIS CIRCUIT, AND WHAT CELL-TYPE CONNECTIONS, WITHIN AND BETWEEN THESE REGIONS, ARE PARTICULARLY ALTERED IN DEPRESSIVE STATES. THE OVERALL OBJECTIVE OF THIS APPLICATION IS TO GENERATE SINGLE-CELL TRANSCRIPTOMIC PROFILES TO STUDY MOLECULAR CHANGES, INCLUDING THOSE SPECIFIC TO GENETIC ANCESTRY AND SEX, ASSOCIATED WITH MDD IN THE MOOD REGULATION CIRCUIT. WHILE DISEASE BURDEN IS GREATER IN AFRICAN AMERICANS, THE IMPACT OF GENETIC ANCESTRY REMAINS UNKNOWN AS MOST GENOMIC STUDIES IN MDD SO FAR HAVE BEEN LIMITED TO SUBJECTS OF EUROPEAN DESCENT. IN ADDITION, PREVIOUS STUDIES REVEALED THAT TRANSCRIPTOMIC CHANGES ASSOCIATED WITH MDD ARE SEX-SPECIFIC, AND GENE NETWORKS ARE DIFFERENTIALLY DYSREGULATED BETWEEN SEXES. THE APPLICANTS' RECENT SINGLE-CELL BRAIN STUDY REVEALED CELL-SPECIFIC CONTRIBUTIONS TO TRANSCRIPTOMIC CHANGES ASSOCIATED WITH MDD. THE PROPOSED PROJECT IS A LARGE-SCALE, SYSTEMATIC INVESTIGATION IN THE ACC, BLA, AND HIPP TO INTERROGATE THE TRANSCRIPTOME AT SINGLE-NUCLEUS RESOLUTION IN AN UNPRECEDENTLY LARGE AND REPRESENTATIVE SAMPLE OF MDD. THE SPECIFIC AIMS ARE TO: 1) IDENTIFY, AT THE SINGLE-CELL LEVEL TRANSCRIPTOMIC CHANGES ASSOCIATED WITH MDD IN 800 SUBJECTS ACROSS THREE LINKED BRAIN REGIONS: ACC, BLA, AND HIPP; 1B) STUDY THE IMPACT OF GENETIC ANCESTRY AND SEX; 2) DEFINE CELL NETWORKS ASSOCIATED WITH MOOD REGULATION USING MACHINE LEARNING APPROACHES; AND 3) IDENTIFY CELL-SPECIFIC EXPRESSION QUANTITATIVE TRAIT LOCI (EQTLS) COLOCALIZING WITH GENOME-WIDE SIGNIFICANT SNPS IDENTIFIED IN MDD GWAS ANALYSES. A LARGE COHORT (N=800) OF HUMAN POST-MORTEM SAMPLES OBTAINED FROM SUBJECTS WITH MDD WILL BE COMPARED TO PSYCHIATRICALLY-HEALTHY CONTROLS. THE SAMPLE (~20% AFRICAN AMERICAN AND ~30% FEMALE) WILL ALLOW FOR STUDYING THE IMPACT OF GENETIC ANCESTRY AND SEX. DROPLET-BASED SINGLE-NUCLEUS RNA SEQUENCING WILL BE APPLIED TO GENERATE TRANSCRIPTOMIC PROFILES. DEEP LEARNING APPROACHES WILL BE USED TO IDENTIFY AND ANNOTATE THE CELL TYPES AND GENE NETWORKS ASSOCIATED MDD. THE LATEST GWAS DATA IN MDD WILL BE LEVERAGED TO FINE MAP GENETIC LOCI WITH CELLULAR AND REGIONAL RESOLUTION. THE PROPOSED RESEARCH IS INNOVATIVE BECAUSE IT IS THE FIRST LARGE-SCALE INVESTIGATION OF THE ACC-BLA-HIPP CIRCUIT IN HUMANS AND WILL REPRESENT THE LARGEST SINGLE-CELL TRANSCRIPTIONAL RESOURCE OF THE HUMAN BRAIN. IT WILL IDENTIFY GENE AND CELLULAR NETWORKS ASSOCIATED WITH SEX OR GENETIC ANCESTRY, AND WILL ALSO GENERATE A VAST AMOUNT OF TRANSCRIPTOMIC DATA ON NEUROTYPICAL BRAINS. THIS RESEARCH IS SIGNIFICANT BECAUSE IT WILL GREATLY ADVANCE OUR UNDERSTANDING OF THE CELLULAR AND MOLECULAR PATHWAYS INVOLVED IN MOOD REGULATION AND MDD. THROUGH A BETTER UNDERSTANDING OF THE MECHANISMS OF DEPRESSIVE ILLNESS, WE MAY BE ONE STEP CLOSER TO DEVELOPING NOVEL TREATMENT STRATEGIES AND PERSONALIZE INTERVENTIONS.